Article
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
European journal of cancer (Oxford, England : 1990) - 1 Aug 2020
Sakai Daisuke, Taniguchi Hiroya, Sugimoto Naotoshi, Tamura Takao, Nishina Tomohiro, Hara Hiroki, Esaki Taito, Denda Tadamichi, Sakamoto Takeshi, Okuda Hiroyuki, Satoh Taroh, Tsushima Takahiro, Makiyama Akitaka, Tsuda Takashi, Hosokawa Ayumu, Kuramochi Hidekazu, Tokunaga Shinya, Moriwaki Toshikazu, Yasui Hisateru, Ishida Hiroyasu, Tsuji Akihito, Otsu Satoshi, Shimokawa Hozumi, Baba Eishi, Sato Mikio, Matsumoto Shigemi, Ozaki Yukinori, Shinozaki Katsunori, Tamagawa Hiroshi, Goto Masahiro, Kadowaki Shigenori, Fujii Hirofumi, Koh Yasuhiro, Yamazaki Kentaro, Hironaka Shuichi, Kishimoto Junji, Boku Narikazu, Hyodo Ichinosuke, Muro Kei
Abstract excerpt
BACKGROUND: Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC). However, it has remained unclear whether panitumumab is effective when combined with irinotecan. We compared efficacies of both regimens in this randomised phase II study. PATIENTS AND METHODS: Patients with wild-type KRAS exon 2 mCRC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.